Additional comment: There were plans to test intermittent maintenance dosing (q 3 months) after a year of monthly treatments in a randomized trial which unfortunately never materialized, so there is no data/evidence, but not an unreasonable alternative to try.

There is no known optimal duration for denosumab in unresectable or metastatic giant cell tumor of bone. Denosumab in this setting may need to be indefinite as long as the tumor is controlled and the drug is well tolerated. After discussion with the patient including the possibility of progression o...